A Trial to Assess Efficacy and Safety of ex Vivo Allograft Admin of iCM012 Solution 2 mg/ml to Improve Its Function in Recipients of DCD Kidneys

Trial statusNot yet recruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age55-75
SponsoriCoat Medical AB

About this trial

Randomized (1:1), placebo controlled, double blind efficacy trial. 200 patients will be followed up for 12 months post transplantation. The primary endpoint will be Delayed Graft Function (DGF) defined as the requirement for dialysis within 7 days post transplantation.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Controlled DCD donors Maastricht category III from 55 to 75 years of age.

Available, personally signed and dated Informed Consent Form.

Male or female chronic kidney disease (CKD) ≥ 18 years of age, on dialysis > 12 months, awaiting their first kidney transplantation.

AB0-compatible, negative pre-transplantation Complement Dependent Cytotoxicity (CDC) and/or flow cytometric class I and II crossmatch, or negative virtual class I and II crossmatch, and no pre-existing donor specific antibodies (Mean Fluorescent Intensity under center specific cut-off for negative value).

Disqualifiers

Surgically induced injuries or anatomical vascular variations compromising ex vivo treatment and/or transplantation outcome, as judged by the investigator.

DCDs with persistent and significant deterioration of kidney function (30% decrease in eGFR from baseline) and/or on dialysis within two (2) weeks prior to organ procurement and/or anuria > 12 hours before surgery.

Extracorporeal membrane oxygenation treatment of the donor

If not tolerating/eligible for thymoglobulin induction and tacrolimus or Cyclosporine A (CyA)-based maintenance immunosuppressants.

Trial design

Design model

Parallel

Treatments tested in this trial

  • iCM012 solution 2 mg/mL

    Drug

    200 mL IMP solution is administered ex vivo by gravity as single infusion through the renal artery/-ies over a period of 5-10 minutes.

  • Placebo

    Drug

    200 mL IMP solution is administered ex vivo by gravity as single infusion through the renal artery/-ies over a period of 5-10 minutes.

Treatment groups

200 Participants
are divided into 2 treatment groups
Group A: Active treatment iCM012 solution 2 mg/mLExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Delayed Graft Function (DGF)

DGF is defined as the need for dialysis within the first 7 postoperative days.

Time frame
First 7 postoperative days.

Secondary outcomes

1

eGFR over 12 months post transplantation

Estimated Glomerular Filtration Rate using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation with four (4) variables (serum creatinine, age, gender, and ethnicity)

Time frame
12 months post transplantation
2

Primary non-function

Primary non-function (PNF) describes the condition in which the kidney never functions adequately after transplantation, and the patient continues to need dialysis despite the transplantation. The diagnosis of PNF generally does not become established before 2 to 3 months after transplantation. Assessed up to 12 months after transplantation

Time frame
12 months post transplantation
3

Number of Participants with prolonged DGF

Number of Participants with prolonged DGF (defined as requirement for dialysis more than 14 days post transplantation)

Time frame
14 days post transplantation
4

Number of Participants with functional DGF

Number of Participants with functional DGF (defined as no serum creatinine decrease by at least 10% daily on 3 consecutive days within the first 7 days post-transplantation)

Time frame
First 7 days post-transplantation

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: